<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5649">
  <stage>Registered</stage>
  <submitdate>24/04/2013</submitdate>
  <approvaldate>24/04/2013</approvaldate>
  <nctid>NCT01842451</nctid>
  <trial_identification>
    <studytitle>A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C</studytitle>
    <scientifictitle>A Phase 2, Multicenter, Randomized, Partially-Blind, Dose-Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Treatment-Naïve Adult Subjects With Genotype 1 Chronic Hepatitis C</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>VX13-135-105</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Hepatitis C</healthcondition>
    <healthcondition>CHC</healthcondition>
    <healthcondition>HCV</healthcondition>
    <healthcondition>Hepatitis C</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - VX-135
Treatment: drugs - Daclatasvir

Experimental: VX-135 High Dose with Daclatasvir - 12 weeks of a high dose of VX-135 in combination with Daclatasvir

Experimental: VX-135 Low Dose with Daclatasvir - 12 weeks of a low dose of VX-135 in combination with Daclatasvir


Treatment: drugs: VX-135


Treatment: drugs: Daclatasvir


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The safety and tolerability as assessed by adverse events (AEs), vital signs, 12-lead electrocardiograms (ECGs), echocardiograms, and laboratory assessments</outcome>
      <timepoint>Up to 64 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The proportion of subjects who have a sustained virologic response (SVR; i.e., HCV RNA concentration below the lower limit of quantitation [&lt;LLOQ; &lt;25 IU/mL]) at 4 weeks after the last planned dose of treatment (SVR4)</outcome>
      <timepoint>Up to 20 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The proportion of subjects who have an SVR at 12 weeks after the last planned dose of treatment (SVR12)</outcome>
      <timepoint>Up to 28 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The proportion of subjects who have an SVR at 44 weeks after the last planned dose of treatment (SVR24)</outcome>
      <timepoint>Up to 40 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The proportion of subjects who have virologic relapse</outcome>
      <timepoint>Up to 64 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The proportion of subjects who have virologic breakthrough</outcome>
      <timepoint>Up to 16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The amino acid sequence of the nonstructural NS5A and NS5B proteins in subjects who have treatment failure</outcome>
      <timepoint>Up to 64 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The proportion of subjects who achieve SVR12 by HCV genotype 1 subtype (1a versus non-1a)</outcome>
      <timepoint>Up to 28 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The proportion of subjects who achieve SVR12 by IL-28B genotype (CC versus non-CC)</outcome>
      <timepoint>Up to 28 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects must have genotype 1 CHC and evidence of HCV infection at least 6 months
             before screening

          -  Subjects must be treatment-naïve and have not received prior treatment with any
             interferon, immunomodulatory agent, or DAA for HCV</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Evidence of cirrhosis

          -  History or other clinical evidence of significant or unstable cardiac disease

          -  Any other cause of significant liver disease in addition to hepatitis C

          -  Creatinine clearance =50 mL/min using the Cockcroft-Gault equation at screening

          -  Female subjects who are pregnant or nursing</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>23</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Vertex Pharmaceuticals Incorporated</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of
      VX-135 and Daclatasvir in Treatment-Naïve Adult Subjects With Genotype 1 Chronic Hepatitis C</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01842451</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>